In the evolving landscape of cancer research, identifying and understanding the role of specific proteins on the surface of cancer cells is crucial. These proteins, known as genes encoding cell surface proteins (GESPs), play a pivotal… Understanding GESPs: What Does ‘Positive Expression’ Mean in Cancer?
The nuclear receptor superfamily comprises 48 ligand-activated transcription factors that regulate a myriad of physiological processes, including metabolism, development, and immune responses. In the context of cancer, these receptors influence tumor initiation, progression, and response to therapies.… Exploring the Nuclear Receptor Superfamily in Cancer via FCG
Functional genomics is revolutionizing cancer research by elucidating the roles of genes and their interactions in tumorigenesis. In 2025, the integration of advanced technologies and methodologies is propelling the field towards more precise and personalized… What’s Next for Functional Cancer Genome Tools?
Cancer remains a leading cause of mortality worldwide, necessitating the continuous exploration of novel biomarkers and therapeutic targets. Nuclear receptors (NRs), a family of 48 ligand-dependent transcription factors, have emerged as pivotal players in cancer biology. … Why Nuclear Receptors Offer Powerful Cancer Biomarkers and Targets
Cancer remains one of the most formidable challenges in modern medicine, with treatment resistance and relapse posing significant hurdles. Recent research highlights the potential of combining Bromodomain and Extra-Terminal (BET) protein inhibition with Poly(ADP-ribose) polymerase (PARP) inhibitors to enhance… How BET Repression and PARP Inhibition Can Combat Cancer—Data from FCG